id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2002-E-0285-0003,FDA,FDA-2002-E-0285,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2004-07-27T04:00:00Z,2004,7,,,2025-10-02T18:42:37Z,,0,0,090000648049ebf8
FDA-2002-E-0285-0002,FDA,FDA-2002-E-0285,Determination of Regulatory Review Period for Purposes of Patent Extension; XIGRIS,Notice,General Notice,2003-11-28T05:00:00Z,2003,11,2003-11-25T05:00:00Z,,2025-10-02T18:39:58Z,03-29333,0,0,090000648049ebf6
FDA-2002-E-0285-0001,FDA,FDA-2002-E-0285,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2003-11-12T05:00:00Z,2003,11,,,2025-10-02T18:22:58Z,,0,0,090000648049ebb0